MA43549A - Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants - Google Patents

Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants

Info

Publication number
MA43549A
MA43549A MA043549A MA43549A MA43549A MA 43549 A MA43549 A MA 43549A MA 043549 A MA043549 A MA 043549A MA 43549 A MA43549 A MA 43549A MA 43549 A MA43549 A MA 43549A
Authority
MA
Morocco
Prior art keywords
alpha
salt
crystalline form
amino esters
polymorphic crystalline
Prior art date
Application number
MA043549A
Other languages
English (en)
Inventor
Jean-Pierre Gotteland
Catherine Jorand-Lebrun
Ernest Loumaye
Page Patrick Naxos
Oliver Pohl
Vincent Pomel
Anna Quattropani
Matthias Schwarz
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/987,586 external-priority patent/US9447055B1/en
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of MA43549A publication Critical patent/MA43549A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pyrrole Compounds (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA043549A 2016-01-04 2017-01-04 Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants MA43549A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662274674P 2016-01-04 2016-01-04
US14/987,586 US9447055B1 (en) 2016-01-04 2016-01-04 α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US201662395664P 2016-09-16 2016-09-16
US201662407918P 2016-10-13 2016-10-13

Publications (1)

Publication Number Publication Date
MA43549A true MA43549A (fr) 2021-05-26

Family

ID=57799697

Family Applications (2)

Application Number Title Priority Date Filing Date
MA043580A MA43580A (fr) 2016-01-04 2017-01-04 L-valinate d'un dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants
MA043549A MA43549A (fr) 2016-01-04 2017-01-04 Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA043580A MA43580A (fr) 2016-01-04 2017-01-04 L-valinate d'un dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants

Country Status (25)

Country Link
EP (4) EP3397622B1 (fr)
JP (6) JP6933322B2 (fr)
KR (3) KR102795275B1 (fr)
CN (1) CN108779087A (fr)
AU (5) AU2017205670B2 (fr)
CA (2) CA3009576A1 (fr)
CY (2) CY1125231T1 (fr)
DK (2) DK3400217T3 (fr)
EA (1) EA036990B1 (fr)
ES (2) ES2916835T3 (fr)
HR (2) HRP20220673T1 (fr)
HU (2) HUE058871T2 (fr)
IL (5) IL318222A (fr)
LT (2) LT3400217T (fr)
MA (2) MA43580A (fr)
MX (3) MX379544B (fr)
PL (2) PL3397622T3 (fr)
PT (2) PT3400217T (fr)
RS (2) RS63286B1 (fr)
SG (4) SG10202009723PA (fr)
SI (2) SI3397622T1 (fr)
SM (2) SMT202200248T1 (fr)
UA (2) UA125377C2 (fr)
WO (2) WO2017118639A1 (fr)
ZA (1) ZA201903769B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202009723PA (en) * 2016-01-04 2020-11-27 ObsEva SA Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
RU2711615C1 (ru) * 2019-09-12 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения эндометриоза на основании экспериментальной модели у крыс
JP2022548314A (ja) * 2019-09-23 2022-11-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery
US20240024295A1 (en) * 2020-12-11 2024-01-25 Elise A. Olsen Compositions and methods for inhibiting hair growth

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835175A (en) 1971-03-15 1974-09-10 Research Corp 9-fluorenylmethanol haloformates, carbonates and thiocarbonates
US3839396A (en) 1971-07-15 1974-10-01 Shionogi & Co 9-lower alkyl-9-fluorenyl carbonates
US4108846A (en) 1977-02-01 1978-08-22 Hoffmann-La Roche Inc. Solid phase synthesis with base N alpha-protecting group cleavage
SE430885B (sv) 1980-03-24 1983-12-19 Ferring Ab Oxytocin-derivat
US4508657A (en) 1982-01-19 1985-04-02 Research Corporation Peptide synthesis and amino acid blocking agents
US4581167A (en) 1982-01-19 1986-04-08 Research Corporation Peptide synthesis and amino acid blocking agents
US4504469A (en) 1982-12-21 1985-03-12 Ferring Ab Vasotocin derivatives
US4460501A (en) 1983-08-30 1984-07-17 Research Corporation Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides
US5370135A (en) * 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy
DE4434488A1 (de) * 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
IN188411B (fr) * 1997-03-27 2002-09-21 Yuhan Corp
CN1444587A (zh) * 2000-05-30 2003-09-24 奥索-麦克尼尔药品公司 二氢吡啶软药及相关组合物和方法
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
DK1480998T3 (da) 2002-02-27 2007-03-26 Ferring Bv Mellemprodukter og fremgangsmåder til fremstilling af heptapeptidoxytocinanaloger
KR20040095311A (ko) * 2002-03-28 2004-11-12 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 프로스타글란딘 ｆ 수용체의 모듈레이터로서의 티아졸리딘카르복사미드 유도체
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
US7598373B2 (en) * 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
JP2013509391A (ja) 2009-10-30 2013-03-14 グラクソ グループ リミテッド （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態
EP2845850A1 (fr) 2013-09-10 2015-03-11 ObsEva S.A. Dérivés de pyrrolidine comme antagonistes des récepteurs V1a de vasopressine/oxytocine
EP2886107A1 (fr) 2013-12-17 2015-06-24 ObsEva S.A. Formules orales de dérivés de pyrrolydine
RU2017100906A (ru) 2014-06-16 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ретосибан для лечения преждевременных родов
AU2015283133B2 (en) 2014-07-02 2019-05-16 ObsEva SA Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity
PL3037101T3 (pl) 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu
US9447055B1 (en) * 2016-01-04 2016-09-20 Merck Serono S.A. α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
SG10202009723PA (en) 2016-01-04 2020-11-27 ObsEva SA Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

Also Published As

Publication number Publication date
IL259742B (en) 2021-08-31
IL260286A (en) 2018-07-31
IL259742A (en) 2018-07-31
MX389261B (es) 2025-03-20
JP2023002668A (ja) 2023-01-10
EA201891095A1 (ru) 2019-01-31
EP3400217B1 (fr) 2022-03-09
RS63285B1 (sr) 2022-06-30
PL3400217T3 (pl) 2022-07-04
MA43580A (fr) 2021-05-26
IL289256A (en) 2022-02-01
LT3397622T (lt) 2022-06-27
JP2019500351A (ja) 2019-01-10
ES2916835T3 (es) 2022-07-06
UA125118C2 (uk) 2022-01-12
IL260286B (en) 2022-02-01
PT3397622T (pt) 2022-06-15
SMT202200249T1 (it) 2022-07-21
JP6933322B2 (ja) 2021-09-08
IL318222A (en) 2025-03-01
SG11201804789QA (en) 2018-07-30
SG11201804594YA (en) 2018-06-28
CY1125231T1 (el) 2025-03-28
EP4140988A1 (fr) 2023-03-01
SG10202009723PA (en) 2020-11-27
DK3397622T3 (en) 2022-06-07
PT3400217T (pt) 2022-06-15
KR102795275B1 (ko) 2025-04-11
CY1125223T1 (el) 2025-03-28
HRP20220673T1 (hr) 2022-07-08
AU2017205670B2 (en) 2021-05-20
MX2018008304A (es) 2019-01-24
ZA201903769B (en) 2023-03-29
AU2021218009B2 (en) 2023-06-22
JP2024012376A (ja) 2024-01-30
HUE058872T2 (hu) 2022-09-28
HRP20220674T1 (hr) 2022-07-22
PL3397622T3 (pl) 2022-07-04
MX2022000154A (es) 2022-02-21
DK3400217T3 (da) 2022-06-07
MX2018008157A (es) 2018-09-03
AU2017205254A1 (en) 2018-08-16
AU2017205254B2 (en) 2021-05-20
KR20180100120A (ko) 2018-09-07
RS63286B1 (sr) 2022-06-30
EP3397622A1 (fr) 2018-11-07
JP2026000959A (ja) 2026-01-06
AU2017205670A1 (en) 2018-08-16
EP4144351A1 (fr) 2023-03-08
AU2025256134A1 (en) 2025-11-13
ES2915948T3 (es) 2022-06-27
JP2021178858A (ja) 2021-11-18
EP3397622B1 (fr) 2022-03-09
CA3009573A1 (fr) 2017-07-13
CN108779087A (zh) 2018-11-09
EP3400217A1 (fr) 2018-11-14
AU2023233151A1 (en) 2023-10-12
SMT202200248T1 (it) 2022-07-21
WO2017118639A1 (fr) 2017-07-13
JP7377588B2 (ja) 2023-11-10
UA125377C2 (uk) 2022-03-02
IL284912B (en) 2022-07-01
KR20180099708A (ko) 2018-09-05
WO2017118641A1 (fr) 2017-07-13
LT3400217T (lt) 2022-06-27
SG10202009769WA (en) 2020-11-27
IL284912A (en) 2021-08-31
HUE058871T2 (hu) 2022-09-28
SI3400217T1 (sl) 2022-07-29
SI3397622T1 (sl) 2022-07-29
JP7169573B2 (ja) 2022-11-11
KR20250107965A (ko) 2025-07-14
AU2021218009A1 (en) 2021-09-09
CA3009576A1 (fr) 2017-07-13
JP7432284B2 (ja) 2024-02-16
MX379544B (es) 2025-03-11
EA036990B1 (ru) 2021-01-25
JP2019501897A (ja) 2019-01-24
AU2021218003A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
EP3438099A4 (fr) Sel d'acide pamoïque de vortioxétine et sa forme cristalline
PL3638666T3 (pl) Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy amidów kwasu tetrahydro- i dihydrofuranokarboksylowego
EP3365344A4 (fr) Sel d'un inhibiteur d'egfr, forme cristalline correspondante et utilisations correspondantes
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
EP3453703A4 (fr) Forme cristalline e d'un sel de tafamidis méthylglucamine, son procédé de préparation et son application
MA46866A (fr) Une forme cristalline d'un inhibiteur de magl
EP3548487A4 (fr) Forme polymorphe de sépiaptérine
EP3337485A4 (fr) Formes cristallines d'ibrutinib
EP3699245A4 (fr) Assortiment d'encres
IL289256A (en) Alpha-amino esters of the hydroxypropylthiazolidine carboxamide derivative and their salt form and crystalline polymorph
EP3668876A4 (fr) Forme polymorphe de tg02
SG11201705924RA (en) CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb>
EP3470410A4 (fr) Forme cristalline du composé supprimant l'activité de la protéine kinase et application associée
MA48944A (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
EP3521276A4 (fr) Forme cristalline, forme de sel, et procédé de préparation d'inhibiteur de tyrosine kinase
EP3896063A4 (fr) Sel d'inhibiteur de syk et forme cristalline correspondante
GB201708390D0 (en) Novel alpha-amino amide derivatives
EP3305768A4 (fr) Sel de sodium d'inhibiteur de transporteur d'acide urique et sa forme cristalline
PL3694843T3 (pl) Nowa sól i nowe stałe postacie escitalopramu
EP3575293A4 (fr) Sel d'éthane-sulfonate de dérivé de quinoléine
PL3515454T3 (pl) Krystaliczna polimorficzna postać 3-hydroksy-4,5-bis-benzyloksy- 6-benzyloksymetylo-2-fenylo-2-okso-2lambda5-[1,2]oksafosfinanu
IL274190A (en) Methods for treating ischemic disease
EP3789389A4 (fr) Forme cristalline de dérivé de thiophène
MA40585A (fr) Sel de dérivé de céphalosporine, forme solide cristalline de celui-ci et son procédé de production
EP3511317A4 (fr) Nouvelle forme cristalline de sel de sodium de sacubitril